Table 2.
Antibiotic resistance profiles for ESBL and non-ESBL E. coli isolates
| Antimicrobial agents (µg) | Diffusion zone (mm) |
ESBL isolates
(n = 8) |
Non-ESBL isolates
(n = 25) |
P value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| S* (%) | I* (%) | R* (%) | S (%) | I (%) | R (%) | |||||
| Streptomycin (10 ) | ≤11 | 0 (0) | 5 (62.5) | 3 (37.5) | 4 (16) | 12 (48) | 9 (36) | 0.01 | ||
| Cefepime (30) | ≤14 | 1 (12.5) | 2 (25) | 5 (62.5) | 13 (52) | 3 (12) | 9 (36) | 0.01 | ||
| Ceftriaxone (30) | ≤13 | 1 (12.5) | 0 (0) | 7 (87.5) | 9 (36) | 4 (16) | 12 (48) | 0.01 | ||
| Amoxicillin-clavulanic acid (20/10) | ≤13 | 0 (0) | 0 (0) | 8 (100) | 1 (4) | 3 (12) | 21 (84) | 0.01 | ||
| Chloramphenicol (30) | ≤12 | 3 (37.5) | 0 (0) | 5 (62.5) | 14 (56) | 1 (4) | 10 (40) | 0.01 | ||
| Ceftazidime (30) | ≤14 | 2 (25) | 2 (25) | 4 (50) | 10 (40) | 2 (8) | 13 (52) | 0.01 | ||
| Ciprofloxacin (5) | ≤15 | 3 (37.5) | 2 (25) | 3 (37.5) | 12 (48) | 5 (20) | 8 (32) | Ns* | ||
| Imipenem (10) | ≤15 | 2 (25) | 1 (12.5) | 5 (62.5) | 16 (64) | 3 (12) | 6 (24) | 0.01 | ||
| Cephalothin (30) | ≤14 | 0 (0) | 0 (0) | 8 (100) | 5 (20) | 0 (0) | 20 (80) | 0.01 | ||
| Cefotaxime (30) | ≤14 | 1 (12.5) | 0 (0) | 7 (87.5) | 7 (28) | 5 (20) | 13 (52) | 0.01 | ||
| Tetracyclines (10) | ≤11 | 0 (0) | 0 (0) | 8 (100) | 4 (16) | 2 (8) | 19 (76) | 0.01 | ||
| Cefuroxime (30) | ≤14 | 0 (0) | 1 (12.5) | 7 (87.5) | 6 (24) | 3 (12) | 16 (64) | 0.01 | ||
| Piperacillin(100) | ≤11 | 7 (87.5) | 1 (12.5) | 0 (0) | 22 (88) | 2 (8) | 1 (4) | Ns | ||